Tags

Type your tag names separated by a space and hit enter

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.
Respir Med Case Rep 2020; 29:100971RM

Abstract

A 64 year old male heating engineer was investigated for a persistent cough and found to have epithelioid mesothelioma with pleural effusion, lung nodules and increased thoracic lymph nodes. He declined standard of care treatment following his own research and he was enrolled in a named patient programme of IMM-101. He was advised to correct his low vitamin D3 level and to start using anti-inflammatories such as aspirin, bromelain and low dose Naltrexone. At review one year later a CT scan showed no change and he continued on the regimen. Four years after the diagnosis a CT scan showed that there was a modest but definite progression of the left malignant pleural thickening, and a new right-sided effusion, enlargement of several intrathoracic nodes which had been noted on the early scans. The chest wall lump eventually broke down and required local radiotherapy. He then developed abdominal pain and found to have peritoneal disease. Last year he obtained the cannabinoids CBD and THC which slowed down the disease and a CT scan after he had been on this for six months, showed that his disease was fairly stable with marginal progression.

Authors+Show Affiliations

St George's University Hospital, London, UK.Oncology, Haematology and Cellular Pathology Guy's and St Thomas' NHS Foundation Trust, London, UK.St George's University Hospital, London, UK.Oxford University Hospitals, Oxford, UK.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

31788420

Citation

Dalgleish, Angus G., et al. "Long-term Benefit From Immune Modulation and Anti-inflammatory Treatment in Metastatic Mesothelioma." Respiratory Medicine Case Reports, vol. 29, 2020, p. 100971.
Dalgleish AG, McLean E, Patel N, et al. Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma. Respir Med Case Rep. 2020;29:100971.
Dalgleish, A. G., McLean, E., Patel, N., & Rahman, N. (2020). Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma. Respiratory Medicine Case Reports, 29, p. 100971. doi:10.1016/j.rmcr.2019.100971.
Dalgleish AG, et al. Long-term Benefit From Immune Modulation and Anti-inflammatory Treatment in Metastatic Mesothelioma. Respir Med Case Rep. 2020;29:100971. PubMed PMID: 31788420.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma. AU - Dalgleish,Angus G, AU - McLean,Emma, AU - Patel,Nirav, AU - Rahman,Najib, Y1 - 2019/11/21/ PY - 2019/10/16/received PY - 2019/11/20/accepted PY - 2019/12/3/entrez PY - 2019/12/4/pubmed PY - 2019/12/4/medline KW - Anti-inflammatory KW - IMM-101-015 KW - Immunotherapy KW - Mesothelioma SP - 100971 EP - 100971 JF - Respiratory medicine case reports JO - Respir Med Case Rep VL - 29 N2 - A 64 year old male heating engineer was investigated for a persistent cough and found to have epithelioid mesothelioma with pleural effusion, lung nodules and increased thoracic lymph nodes. He declined standard of care treatment following his own research and he was enrolled in a named patient programme of IMM-101. He was advised to correct his low vitamin D3 level and to start using anti-inflammatories such as aspirin, bromelain and low dose Naltrexone. At review one year later a CT scan showed no change and he continued on the regimen. Four years after the diagnosis a CT scan showed that there was a modest but definite progression of the left malignant pleural thickening, and a new right-sided effusion, enlargement of several intrathoracic nodes which had been noted on the early scans. The chest wall lump eventually broke down and required local radiotherapy. He then developed abdominal pain and found to have peritoneal disease. Last year he obtained the cannabinoids CBD and THC which slowed down the disease and a CT scan after he had been on this for six months, showed that his disease was fairly stable with marginal progression. SN - 2213-0071 UR - https://www.unboundmedicine.com/medline/citation/31788420/Long-term_benefit_from_immune_modulation_and_anti-inflammatory_treatment_in_metastatic_mesothelioma L2 - https://linkinghub.elsevier.com/retrieve/pii/S2213-0071(19)30316-8 DB - PRIME DP - Unbound Medicine ER -